Preoperative Systemic Inflammatory Markers as a Significant Prognostic Factor After TURBT in Patients with Non-Muscle-Invasive Bladder Cancer

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Ca Cancer J Clin. 2022;72:7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage ta t1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–477. doi:10.1016/j.eururo.2005.12.031
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus calmette-guerin: the cueto scoring model. J Urol. 2009;182:2195–2203. doi:10.1016/j.juro.2009.07.016
   PubMed Web of Science ®Google Scholar
• Fujii Y. Prediction models for progression of non-muscle-invasive bladder cancer: a review. Int J Urol. 2018;25:212–218. doi:10.1111/iju.13509
   PubMed Web of Science ®Google Scholar
• Bree KK, Shan Y, Hensley PJ, et al. Management, surveillance patterns, and costs associated with low-grade papillary stage ta non–muscle-invasive bladder cancer among older adults, 2004–2013. JAMA Netw Open. 2022;5:e223050. doi:10.1001/jamanetworkopen.2022.3050
   Web of Science ®Google Scholar
• Koie T, Ohyama C, Hosogoe S, et al. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Int Urol Nephrol. 2015;47:1509–1514. doi:10.1007/s11255-015-1048-3
   Web of Science ®Google Scholar
• Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. J Urol. 2011;186:2158–2167. doi:10.1016/j.juro.2011.07.076
   PubMed Web of Science ®Google Scholar
• Konety B, Isharwal S. Non-muscle invasive bladder cancer risk stratification. Indian J Urol. 2015;31:289. doi:10.4103/0970-1591.166445
   Google Scholar
• Kobayashi S, Fujii Y, Koga F, et al. Impact of bladder neck involvement on progression in patients with primary non–muscle invasive bladder cancer: a prospective validation study. Urol Oncol. 2014;32:29–38. doi:10.1016/j.urolonc.2013.04.001
   Web of Science ®Google Scholar
• Zhan X, Guo J, Chen L, et al. Prognostic significance of bladder neck involvement in non‐muscle‐invasive bladder cancer: a seer database analysis with 19,919 patients. Cancer Med. 2021;10:6868–6880. doi:10.1002/cam4.4219
   Web of Science ®Google Scholar
• Fukushima H, Moriyama S, Waseda Y, et al. Significance of bladder neck involvement in risk substratification of intermediate-risk non–muscle-invasive bladder cancer. Eur Urol Focus. 2021;7:366–372. doi:10.1016/j.euf.2020.01.006
   Google Scholar
• Ye F, Liang Y, Hu J, et al. DNA methylation modification map to predict tumor molecular subtypes and efficacy of immunotherapy in bladder cancer. Front Cell Dev Biol. 2021;9:760369. doi:10.3389/fcell.2021.760369
   Web of Science ®Google Scholar
• Ye F, Liang Y, Cheng Z, et al. Immunological characteristics of alternative splicing profiles related to prognosis in bladder cancer. Front Immunol. 2022;13:911902. doi:10.3389/fimmu.2022.911902
   Web of Science ®Google Scholar
• Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004;30:95–108. doi:10.1055/s-2004-822974
   PubMed Web of Science ®Google Scholar
• Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost. 2007;33:712–721. doi:10.1055/s-2007-991540
   PubMed Web of Science ®Google Scholar
• Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 2019;40:228–242. doi:10.1016/j.it.2019.01.006
   PubMed Web of Science ®Google Scholar
• Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14:173. doi:10.1186/s13045-021-01187-y
   PubMed Web of Science ®Google Scholar
• Ohno Y. Role of systemic inflammatory response markers in urological malignancy. Int J Urol. 2019;26:31–47. doi:10.1111/iju.13801
   Web of Science ®Google Scholar
• Hu H, Yao X, Xie X, et al. Prognostic value of preoperative nlr, dnlr, plr and crp in surgical renal cell carcinoma patients. World J Urol. 2017;35:261–270. doi:10.1007/s00345-016-1864-9
   PubMed Web of Science ®Google Scholar
• Barua SK, Singh Y, Baruah SJ, et al. Predictors of progression-free survival and overall survival in metastatic non-clear cell renal cell carcinoma: a single-center experience. World J Oncol. 2019;10:101–111. doi:10.14740/wjon1188
   PubMedGoogle Scholar
• Vartolomei MD, Porav-Hodade D, Ferro M, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (nlr) in patients with non–muscle-invasive bladder cancer (nmibc): a systematic review and meta-analysis. Urol Oncol. 2018;36:389–399. doi:10.1016/j.urolonc.2018.05.014
   PubMed Web of Science ®Google Scholar
• Yıldız HA, Değer MD, Aslan G. Prognostic value of preoperative inflammation markers in non‐muscle invasive bladder cancer. Int J Clin Pract. 2021;75:e14118. doi:10.1111/ijcp.14118
   Web of Science ®Google Scholar
• Mano R, Baniel J, Shoshany O, et al. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non–muscle-invasive bladder cancer. Urol Oncol. 2015;33:61–67. doi:10.1016/j.urolonc.2014.06.010
   Google Scholar
• Mbeutcha A, Shariat SF, Rieken M, et al. Prognostic significance of markers of systemic inflammatory response in patients with non–muscle-invasive bladder cancer. Urol Oncol. 2016;34:417–483. doi:10.1016/j.urolonc.2016.05.013
   Web of Science ®Google Scholar
• Cantiello F, Russo GI, Vartolomei MD, et al. Systemic inflammatory markers and oncologic outcomes in patients with high-risk non–muscle-invasive urothelial bladder cancer. Eur Urol Oncol. 2018;1:403–410. doi:10.1016/j.euo.2018.06.006
   PubMed Web of Science ®Google Scholar
• Pikuła A, Skórzewska M, Pelc Z, et al. Prognostic value of systemic inflammatory response markers in patients undergoing neoadjuvant chemotherapy and gastrectomy for advanced gastric cancer in the Eastern European population. Cancers. 2022;14:1997. doi:10.3390/cancers14081997
   Google Scholar
• Savioli F, Morrow ES, Dolan RD, et al. Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis. Br J Surg. 2022;109:1206–1215. doi:10.1093/bjs/znac319
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kawada K, Obama K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int J Mol Sci. 2021;22:8002. doi:10.3390/ijms22158002
   PubMed Web of Science ®Google Scholar
• Zou Y, Xie J, Zheng S, et al. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg. 2022;107:106936. doi:10.1016/j.ijsu.2022.106936
   Web of Science ®Google Scholar
• Wu R, Li D, Zhang F, Bai Y, Wang X, Han P. Prognostic value of platelet-to-lymphocyte ratio in non-muscle invasive bladder cancer patients: intravesical bacillus calmette-guerin treatment after transurethral resection of bladder tumor. Front Surg. 2022;9:907485. doi:10.3389/fsurg.2022.907485
   Web of Science ®Google Scholar
• Pfeffer C, Singh A. Apoptosis: a target for anticancer therapy. Int J Mol Sci. 2018;19:448. doi:10.3390/ijms19020448
   PubMed Web of Science ®Google Scholar
• Waseda Y, Inoue M, Ito M, et al. Mp15-04 new predictive scoring model for recurrence incorporating bladder neck involvement in patients with non-muscle-invasive bladder cancer. J Urol. 2017;197:e172. doi:10.1016/j.juro.2017.02.489
   Web of Science ®Google Scholar
• Fujii Y, Fukui I, Kihara K, et al. Significance of bladder neck involvement on progression in superficial bladder cancer. Eur Urol. 1998;33:464–468. doi:10.1159/000019636
   PubMed Web of Science ®Google Scholar
• van Rhijn BWG, Zuiverloon TCM, Vis AN, et al. Molecular grade (fgfr3/mib-1) and EORTC risk scores are predictive in primary non–muscle-invasive bladder cancer. Eur Urol. 2010;58:433–441. doi:10.1016/j.eururo.2010.05.043
   PubMed Web of Science ®Google Scholar
• Claps F, Mir MC, Zargar H. Molecular markers of systemic therapy response in urothelial carcinoma. Asian J Urol. 2021;8:376–390. doi:10.1016/j.ajur.2021.05.001
   PubMed Web of Science ®Google Scholar
• Mertens LS, Claps F, Mayr R, et al. Prognostic markers in invasive bladder cancer: fgfr3 mutation status versus p53 and ki-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urol Oncol. 2022;40:110–111. doi:10.1016/j.urolonc.2021.10.010
   Web of Science ®Google Scholar
• de Kruijff IE, Beije N, Martens J, de Wit R, Boormans JL, Sleijfer S. Liquid biopsies to select patients for perioperative chemotherapy in muscle-invasive bladder cancer: a systematic review. Eur Urol Oncol. 2021;4:204–214. doi:10.1016/j.euo.2020.01.003
   Web of Science ®Google Scholar
• van Osch FH, Jochems SH, van Schooten F, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol. 2016;45:857–870. doi:10.1093/ije/dyw044
   PubMed Web of Science ®Google Scholar
• Freedman ND. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737. doi:10.1001/jama.2011.1142
   PubMed Web of Science ®Google Scholar